CLINICAL_TRIALS
trial_result
· 2012-08-28
Clinical Trial Update: Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) [Phase 1, Phase 2]
Summary
Phase 1/2 trial of lomustine (CCNU) plus dasatinib in recurrent glioblastoma was terminated; results were posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-08-28